13F Pro13F Pro

Casdin Capital, LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1534261
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$2.0B

AUM History

13fpro.ai/research/fund/casdin-capital-llc-1534261

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/casdin-capital-llc-1534261

Casdin Capital, LLC 13F holdings — Q2 2026

$2.0B portfolio (+51.3% QoQ) · 43 holdings · Q2 2026 13F · top 10 are 77% of the stock portfolio

All holdings — Casdin Capital, LLC (Q2 2026)

43 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
TXG$TXG10x Genomics, Inc.$40.3M-54%
SRRK$SRRKScholar Rock Holding Corp$36.6M+90%
PSNL$PSNLPersonalis, Inc.$34.2M+59%
GRAL$GRALGRAIL, Inc.$32.8M+109%
GH$GHGuardant Health, Inc.$27.8M-41%
MAZE$MAZEMaze Therapeutics, Inc.$25.2M+11%
HIMS$HIMSHims & Hers Health, Inc.$24.3M—
ALNY$ALNYALNYLAM PHARMACEUTICALS, INC.$22.6M—
TSHA$TSHATaysha Gene Therapies, Inc.$22.1M—
AGMB$AGMBAgomAb Therapeutics NVadr$20.1M—
SEPN$SEPNSepterna, Inc.$18.5M—
PBLS$PBLSParabilis Medicines, Inc.$17.7MNew
SION$SIONSionna Therapeutics, Inc.$17.6MNew
VCYT$VCYTVERACYTE, INC.$16.2M—
ANL$ANLAdlai Nortye Group Ltd.adr$14.4M+132%

What changed in Q2 2026

Against the previous quarter's 13F: 6 new, 9 added to, 3 trimmed, 3 sold out. Share-count changes; largest moves by dollar size first.

New positions (6)

  • PBLS$PBLSParabilis Medicines, Inc.$17.7M

    first bought this quarter

  • SION$SIONSionna Therapeutics, Inc.$17.6M

    first bought this quarter

  • SRPT$SRPTSarepta Therapeutics, Inc.$8.4M

    first bought this quarter

  • QURE$QUREuniQure N.V.$6.9M

    first bought this quarter

  • EDIT$EDITEditas Medicine, Inc.$1.4M

    first bought this quarter

  • KARD$KARDKardigan, Inc.$1.2M

    first bought this quarter

Added to (9)

  • WGS$WGSGeneDx Holdings Corp.+23%

    now $254.5M · held 11+ qtrs

  • RLAY$RLAYRelay Therapeutics, Inc.+11%

    now $300.0M · held 11+ qtrs, 3 adds in a row

  • SRRK$SRRKScholar Rock Holding Corp+90%

    now $36.6M · held 3 qtrs, 3 adds in a row

  • GRAL$GRALGRAIL, Inc.+109%

    now $32.8M · held 2 qtrs, 2 adds in a row

  • PSNL$PSNLPersonalis, Inc.+59%

    now $34.2M · held 2 qtrs, 2 adds in a row

  • ANL$ANLAdlai Nortye Group Ltd.+132%

    now $14.4M · held 2 qtrs, 2 adds in a row

+3 more in the Excel export

Trimmed (3)

  • TXG$TXG10x Genomics, Inc.-54%

    now $40.3M · held 3 qtrs

  • BLFS$BLFSBIOLIFE SOLUTIONS INC-22%

    now $131.5M · held 11+ qtrs

  • GH$GHGuardant Health, Inc.-41%

    now $27.8M · held 9 qtrs, 2 trims in a row

Sold out (3)

  • QGEN$QGENQIAGEN N.V.was $14.4M

    held 1 qtr

  • TEM$TEMTempus AI, Inc.was $13.3M

    held 3 qtrs

  • MLTX$MLTXMoonLake Immunotherapeuticswas $8.4M

    held 1 qtr

Firm AUM (Form ADV): $2.9B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Casdin Capital, LLC has filed, 37 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Casdin Capital?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Casdin Capital's top 20 holdings: 37/100 (our AI quality score, weighted by position size; 15 of the 20 are scored)

Top 10 since filing

-12.3%

Value-weighted move of the 10 largest stock positions

Turnover

8%

Last quarter; 33% over the last 4

Top 10 weight

77%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

86%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2023 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Casdin Capital, LLC disclosed 43 positions worth $2.0B in its Form 13F-HR for Q2 2026, led by $RVMD (Revolution Medicines, Inc.) at 24.2% of the equity portfolio, followed by $RLAY and $WGS. During the quarter the fund opened 6 new positions and exited 3 — including a new stake in $PBLS and a full exit from $QGEN. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Casdin Capital, LLC’s Form 13F-HR filing with the SEC under CIK 1534261.

Funds like this

managers whose biggest positions overlap Casdin Capital's
Nextech Invest, Ltd.$2.11B 13F book · 4 shared top holdingsRVMDRLAYPBLSGLUEFARALLON CAPITAL MANAGEMENT LLC$21.68B 13F book · 5 shared top holdingsRVMDBEAMGRALPBLSParadigm Biocapital Advisors LP$5.34B 13F book · 4 shared top holdingsRVMDALNYEDITKARDBVF INC/IL$3.91B 13F book · 5 shared top holdingsRVMDGPCRABSIIRONBAKER BROS. ADVISORS LP$19.96B 13F book · 6 shared top holdingsRVMDGRALDNLIGPCRDAFNA Capital Management LLC$524.36M 13F book · 6 shared top holdingsRVMDDNLINGNEANL

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Casdin Capital, LLC

13F Pro is an AI hedge fund tracker and stock research platform. For Casdin Capital, LLC (SEC CIK: 1534261), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Casdin Capital, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.